Approaches to Mask the Bitter Taste of Pharmaceuticals for Improved Therapeutic Efficacy

Abstract

Abstract

Purpose

Bitterness is a significant barrier to patient adherence with oral medications, particularly in vulnerable populations such as children and the elderly. This dissertation investigates taste-masking strategies, specifically focusing on ibuprofen formulations, and applies the Quality by Design (QbD) framework to enhance therapeutic efficacy through patient centered drug development.

Methods

A systematic literature review was conducted following PRISMA guidelines. Over 5,000 articles were screened to identify studies on pharmaceutical taste masking and compliance outcomes. The taste-masking strategies were classified into four categories: chemical, physical, organoleptic, and receptor-blocking approaches. Building on these insights, a case study on pediatric oral ibuprofen dry emulsion was undertaken, interpreted through QbD methodology. Critical quality attributes (CQAs), material attributes (CMAs), and process parameters (CPPs) were identified using Failure Modes and Effects Analysis (FMEA). A Design of Experiments (DoE) approach was applied to optimize formulation factors, with the aim of balancing palatability, dissolution, and stability.

Results

The review revealed that no single method universally achieves effective taste masking. However, cyclodextrin complexation, ion exchange resins, and lipid encapsulation emerged as particularly effective strategies for highly bitter active pharmaceutical ingredients (APIs). In the case study of ibuprofen, QbD principles provided a structured framework for defining a Quality Target Product Profile (QTPP), which linked CQAs to process parameters. Compared to conventional empirical approaches, the QbD-based strategy offered clearer mechanistic insights, reduced the experimental burden, and enhanced robustness in controlling formulation variability. The dry emulsion system effectively reduced bitterness perception and demonstrated improved bioavailability while ensuring attributes suitable for pediatric use.

Conclusions

This research emphasizes the importance of integrating taste masking into patient-centric pharmaceutical design. The application of QbD principles transforms formulation development from trial-and-error methods into proactive, risk-based, and scientifically grounded strategies. The outcomes demonstrate that QbD not only strengthens the consistency and regulatory acceptability of taste-masked formulations but also directly improves patient compliance and therapeutic success.

Keywords: Bitter taste, Taste-Masking Approaches, Patient Adherence, Children, Quality by Design, QbD.